Sign in Subscribe
Endocrinology

Breakthrough in Diabetic Peripheral Neuropathy Diagnosis and Management

Strategic Insights

— 1 min read

NeuroMetrix, Inc. has made an important advance in the management of diabetic peripheral neuropathy (DPN), a condition that affects over 18 million Americans. According to the American Diabetes Association, over half of diabetes patients have DPN, and as many as three-quarters are unaware of their nerve degeneration until symptoms appear. The FDA's priority approval of Cymbalta (duloxetine HCl) has highlighted the need for accurate diagnosis and treatment of DPN. Nerve conduction studies (NCS) are the most accurate way to diagnose and stage DPN, and the NeuroMetrix NC-stat System allows all physicians to perform NCS in their practice.

Key Takeaways:

  • Over 18 million Americans have diabetes, with over half suffering from diabetic peripheral neuropathy (DPN).
  • DPN can lead to pain, unusual sensations, and numbness, affecting up to three-quarters of DPN patients.
  • Nerve conduction studies (NCS) are the most accurate and objective way to diagnose and stage DPN.
  • The NeuroMetrix NC-stat System allows all physicians to perform NCS in their practice, eliminating the need for referrals to specialists.
  • The NC-stat System has been adopted by over 1,900 physician practices, enabling thousands of physicians to rapidly and accurately diagnose DPN.
  • The FDA's priority approval of Cymbalta (duloxetine HCl) was supported by studies using the NC-stat System, which demonstrated the drug's safety and efficacy.
  • NeuroMetrix, Inc. is a medical device company focused on designing, developing, and selling proprietary products for DPN diagnosis.
  • The approval of Cymbalta delivers greater therapeutic options for patients and physicians.

Statistics:

  • Over 18 million Americans have diabetes.
  • Over half of diabetes patients have diabetic peripheral neuropathy (DPN).
  • Up to three-quarters of DPN patients are unaware of their nerve degeneration until symptoms appear.
  • The NeuroMetrix NC-stat System has been adopted by over 1,900 physician practices.
  • The NC-stat System enables thousands of physicians to rapidly and accurately diagnose DPN.

Sources:

  • American Diabetes Association
  • NeuroMetrix, Inc. (Nasdaq:NURO)
  • Food and Drug Administration (FDA)
  • Lilly Research Laboratories
  • Pharma Business Week
  • NewsRx.com
  • NewsRx.net

Read more